Harvard Bioscience $HBIO beat on both lines: revenue rose 8% to $22.2M (vs $21.85M est.), and the adjusted loss of $0.06/share was far better than the $0.27 exp

Harvard Bioscience $HBIO beat on both lines: revenue rose 8% to $22.2M (vs $21.85M est.), and the adjusted loss of $0.06/share was far better than the $0.27 expected. Shares traded near $9.12 premarket, close to the 52-week high. But adjusted gross margin compressed to 57.1% from 59.2%, and managem…